依达拉奉治疗脑出血60例疗效观察

依达拉奉右莰醇治疗出血性脑梗死患者的效果观察李东升①　李妙婷① 【摘要】　目的：观察依达拉奉右莰醇治疗出血性脑梗死（HI）患者的效果。

方法：以2020年10月—2022年2月福建医科大学附属漳州市医院收治的80例HI患者为研究对象，采用电脑随机数表法分为观察组和对照组，各40例。

两组均予以常规药物，在此基础上，对照组予依达拉奉，观察组予依达拉奉右莰醇。

比较两组总有效率、Fugl-Meyer量表（FMA）评分、Barthel指数量表（BI）评分、神经功能缺损程度量表（NDS）评分、炎症指标水平、N-末端脑钠肽前体（NT-proBNP）水平及不良反应发生情况。

结果：观察组总有效率为90.00%，高于对照组的72.50%，差异有统计学意义（P<0.05）。

治疗后，观察组FMA评分、BI评分高于对照组，NDS评分低于对照组，差异有统计学意义（P<0.05）。

治疗后，两组白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）、同型半胱氨酸（Hcy）均低于治疗前，且观察组低于对照组，差异有统计学意义（P<0.05）。

治疗后，两组NT-proBNP低于治疗前，且观察组NT-proBNP低于对照组，差异有统计学意义（P<0.05）。

两组不良反应发生率比较，差异无统计学意义（P>0.05）。

结论：依达拉奉右莰醇治疗HI效果显著，能改善患者神经功能，抑制机体炎症反应，调控神经因子，提高自理能力。

【关键词】　脑梗死　依达拉奉右莰醇　神经功能 doi：10.14033/ki.cfmr.2023.21.017 文献标识码　B 文章编号　1674-6805（2023）21-0067-04 Effect of Edaravone and Dexborneol in the Treatment of Patients with Hemorrhagic Cerebral Infarction/LI Dongsheng, LI Miaoting. //Chinese and Foreign Medical Research, 2023, 21(21): 67-70 [Abstract]　Objective: To observe the effect of Edaravone and Dexborneol in the treatment of patients with hemorrhagic cerebral infarction (HI). Method: A total of 80 patients with HI admitted to Zhangzhou Affiliated Hospital of Fujian Medical University from October 2020 to February 2022 were selected as the research objects. They were divided into observation group and control group by computer random number table method, with 40 cases in each group. Both groups were given conventional drugs. On this basis, the control group was given Edaravone, and the observation group was given Edaravone and Dexborneol. The total effective rate, Fugl-Meyer assessment scale (FMA) score, Barthel index scale (BI) score, neurological deficit scale (NDS) score, inflammatory index level, N-terminal brain natriuretic peptide precursor (NT-proBNP) level and the occurrence of adverse reactions were compared between the two groups. Result: The total effective rate of observation group was 90.00%, which was higher than 72.50% of the control group, the difference was statistically significant (P<0.05). After treatment, FMA score and BI score in the observation group were higher than those in the control group, and NDS score was lower than that in the control group, the differences were statistically significant (P<0.05). After treatment, interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and homocysteine (Hcy) in two groups were lower than those before treatment, and observation group were lower than those in the control group, the differences were statistically significant (P<0.05). After treatment, NT-proBNP in the two groups were lower than those before treatment, and NT-proBNP in the observation group was lower than that in the control group, the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Edaravone and Dexborneol is effective in the treatment of HI, which can improve neurological function, inhibit inflammation, regulate neurofactors and improve self-care ability. [Key words]　Cerebral infarction　Edaravone and Dexborneol　Neurological function First-author's address: Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, China 出血性脑梗死（HI）为临床常见急性脑血管疾病，占脑梗死比例高达43%，其要特征为继发性出血，由梗死灶内病变血管发生渗血引起，具有高致死率及高致残率等特点[1]。

依达拉奉治疗急性脑出血的疗效分析急性脑出血是一种严重的神经系统疾病，由于其发病突然、病情危重等特点，给患者以及家属带来了严重的生理和心理负担。

近年来，随着医疗技术的不断发展，依达拉奉治疗急性脑出血的疗效得到了广泛认可。

下面将对依达拉奉治疗急性脑出血的疗效进行分析。

首先，依达拉奉是一种强效神经保护剂，能够抑制脑细胞的自由基生成和炎症反应，保护神经细胞免受损伤。

研究表明，依达拉奉可以减轻脑出血后的神经组织病变和细胞凋亡，并促进神经元的恢复。

因此，依达拉奉治疗急性脑出血可以有效减少病人的神经系统损伤，提高其生活质量。

其次，依达拉奉能够促进急性脑出血的吸收和减轻脑水肿。

脑出血后会产生一定的炎症反应和水肿，这些都会加重脑损伤的程度。

而依达拉奉可以通过抑制炎症反应和清除自由基来减轻脑水肿，缩小脑损伤范围。

实验研究也证实，依达拉奉可以增加脑组织的代谢和脑血流灌注，促进脑损伤的修复。

再次，依达拉奉可以改善血管功能，减少血管痉挛。

急性脑出血后，血管周围的肌肉会收缩，导致血管痉挛和缺血等情况。

这些都会进一步加重脑损伤。

而依达拉奉可以通过扩张血管、降低血压和减少炎症等方式来改善血管功能，保证血流供应，缓解血管痉挛。

综上所述，依达拉奉是一种安全有效的治疗急性脑出血的药物。

其主要治疗作用包括保护神经细胞、促进吸收和减轻脑水肿、改善血管功能和减少血管痉挛等。

这些疗效的出现不仅可以减轻病人的痛苦，也有助于提高其生活质量。

但是，需要注意的是，由于每位病人的情况不同，治疗效果也会有所差异。

因此，在使用依达拉奉治疗急性脑出血时，应该根据患者的实际情况综合考虑，做出科学合理的治疗方案。